SCHEMBL5451660

SCHEMBL5451660

CCN(CC)C(=S)NC(=O)c1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.68
LMNA P02545 3/20 0.68
KDM4E B2RXH2 1/20 0.68
HTT P42858 3/20 0.66
L3MBTL1 Q9Y468 3/20 0.66
GAA P10253 2/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
ALOX12 P18054 3/20 0.57
NPSR1 Q6W5P4 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
TDP1 Q9NUW8 1/20 0.56
GPR55 Q9Y2T6 1/20 0.56
HPGD P15428 2/20 0.55
CCR6 P51684 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7063202 0.85 ALDH1A1 (0.69) ALDH1A1LMNAKDM4EHTTL3MBTL1
SCHEMBL5447985 0.83 ALDH1A1 (0.66) ALDH1A1LMNAKDM4EHTTL3MBTL1
SCHEMBL16587387 0.83 ALDH1A1 (0.61) ALDH1A1LMNAKDM4EHTTL3MBTL1
SCHEMBL5457229 0.82 ALDH1A1 (0.57) ALDH1A1LMNAKDM4EHTTL3MBTL1
SCHEMBL10400661 0.80 PKM (0.66) ALDH1A1LMNAKDM4EHTTL3MBTL1
SCHEMBL9602160 0.79 ALDH1A1 (0.84) ALDH1A1LMNAKDM4EHTTL3MBTL1
SCHEMBL4399822 0.79 ALDH1A1 (0.47) ALDH1A1LMNAKDM4EHTTL3MBTL1
SCHEMBL4393320 0.79 ALDH1A1 (0.47) ALDH1A1LMNAKDM4EHTTL3MBTL1
SCHEMBL12069272 0.79 ALDH1A1 (0.54) ALDH1A1LMNAKDM4EHTTL3MBTL1
SCHEMBL4393412 0.79 ALDH1A1 (0.47) ALDH1A1LMNAKDM4EHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112805345-A Two-part cyanoacrylate/free radically curable adhesive systems 汉高知识产权控股有限责任公司 2021-05-14 CN claimed
CN-112805345-B Two-part cyanoacrylate/free radical curable adhesive system 汉高股份有限及两合公司 2023-12-08 CN disclosed
EP-3612609-B1 ADHESIVE COMPOSITIONS HENKEL AG & CO KGAA (DE) 2022-12-28 EP disclosed
US-20210171810-A1 Two Step Adhesive System HENKEL AG & CO. KGAA (DE) 2021-06-10 US disclosed
CN-112805345-A Two-part cyanoacrylate/free radically curable adhesive systems 汉高知识产权控股有限责任公司 2021-05-14 CN disclosed
US-10590311-B2 Accelerators for two part curable compositions Henkel IP & Holding GmbH (DE) 2020-03-17 US disclosed
WO-2020035580-A1 TWO STEP ADHESIVE SYSTEMS Henkel IP & Holding GmbH (DE) 2020-02-20 WO disclosed
US-9371473-B2 Accelerators for two step adhesive systems Henkel IP & Holding GmbH (DE) 2016-06-21 US disclosed
US-9371473-B2 Accelerators for two step adhesive systems Henkel IP & Holding GmbH (DE) 2016-06-21 US disclosed
US-9365750-B2 Accelerators for curable compositions Henkel IP & Holding GmbH (DE) 2016-06-14 US disclosed
US-9365750-B2 Accelerators for curable compositions Henkel IP & Holding GmbH (DE) 2016-06-14 US disclosed
US-8986847-B2 Accelerator/oxidant/proton source combinations for two part curable compositions Henkel IP & Holding GmbH (DE) 2015-03-24 US disclosed
US-8986847-B2 Accelerator/oxidant/proton source combinations for two part curable compositions Henkel IP & Holding GmbH (DE) 2015-03-24 US disclosed
US-20120295890-A1 GLYCOSAMINOGLYCAN INHIBITORS Zacharon Pharmaceutical, Inc. (US) 2012-11-22 US disclosed
US-20070040151-A1 Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems HERAEUS KULZER GMBH (DE) 2007-02-22 US disclosed
US-5262072-A Stabilization of a lubricant or hydraulic fluid against oxidation and/or heat degradation CIBA-GEIGY CORPORATION (US) 1993-11-16 US disclosed
US-4980071-A PRECIPITATION OF HEAVY METAL COMPOUNDS; WASTE WATER TREATMENT DEGUSSA AKTIENGESELLSCHAFT (DE) 1990-12-25 US disclosed
US-4571266-A USING THIOUREA EXTRACTING AGENT DEGUSSA AKTIENGESELLSCHAFT (DE) 1986-02-18 US disclosed
US-4571265-A Process for separation and purification of platinum group metals (II) DEGUSSA AKTIENGESELLSCHAFT (DE) 1986-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295890-A1 GLYCOSAMINOGLYCAN INHIBITORS CSGALNACT1, FUT5, ST3GAL3 ALDH1A1 797/4885LMNA 3422/4885KDM4E 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.